AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUL 214 min read$VYNE

VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

VYNE Therapeutics (Nasdaq: VYNE) said its board approved a 1-for-50 reverse stock split ahead of its proposed merger with Yarrow Bioscience. After the merger, trading is expected to start July 27 under Yarrow Bioscience (Nasdaq: YARW). VYNE also updated a $17.3 million special cash dividend, about $0.40242 per share, with due bill rules around the record and payment dates.

Original reporting
finanznachrichten.de
Published Jul 21, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$VYNE
Neutral
high confidence
Mentioned
$VYNE
Relevance
9/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$VYNENeutralHigh
01

Why it matters

The 1-for-50 reverse split will reduce outstanding shares and adjust equity award terms, while the $17.3M special cash dividend introduces due-bill trading and a defined ex-dividend date. Together, these can drive volatility and settlement-driven price distortions around the record and payment dates and into the merger close window.

02

Market read

Traders need to account for reverse-split price scaling, dividend entitlement via due bills, and the merger-close timing window when positioning around July 21-24.

03

What to watch

Due-bill procedures can cause buyer/seller entitlement mismatches and brokerage processing issues, potentially amplifying short-term dislocations unrelated to fundamentals.

Relevance 9/10Novelty 8/10Timing: Into the July 21 due-bill start, July 22 record date, July 23 payment date, and July 24 ex-dividend date, ahead of merger close around July 24.

Background

VYNE is pursuing a proposed merger with Yarrow Bioscience, and this release ties the reverse split and dividend mechanics to the anticipated closing timeline.

Company-level read

Ticker impact

$VYNENeutralHigh confidence
Context

VYNE approved a 1-for-50 reverse split tied to the proposed merger closing and updated a $17.3M special cash dividend schedule.

Expected impact

Likely elevated volatility into the July 22 record date, July 23 payment date, and July 24 ex-dividend date, with liquidity/price distortions from the 1-for-50 split.

Evidence & confidence

The article discloses concrete corporate-action dates, dividend per-share math, due-bill treatment, and the expected merger close window, all of which directly affect trading behavior and settlement.

Market effects

Sector

Limited direct sector read-across; this is primarily a microcap corporate-action and M&A execution event.

Regional

Mostly US-focused trading effects on Nasdaq-listed small-cap biotech liquidity and settlement.

Global

Low, as the disclosed catalysts are company-specific and tied to US market structure (Nasdaq due bills, ex-dividend timing).

Counterpoint

What could challenge this read

The reverse split and dividend may be largely mechanical, so price action could fade after the ex-dividend date if merger-close odds are unchanged.

Key entities

  • public_company
    VYNE Therapeutics Inc.

    Nasdaq-listed company announcing a 1-for-50 reverse stock split and a $17.3M special cash dividend update tied to the proposed merger with Yarrow.

  • public_company
    Yarrow Bioscience, Inc.

    Proposed merger counterparty; post-merger expected to trade under the new name Yarrow Bioscience, Inc. with ticker YARW.

Read at source← All news

Also covered by

1 outlet

Related articles

JUL 29
$VYNEMed

Yarrow Bioscience merges with VYNE Therapeutics

RTW Biotech Opportunities said Yarrow Bioscience completed its merger with VYNE Therapeutics, alongside about $200m in private financings led by RTW. The combined company began Nasdaq trading as Yarrow Bioscience under ticker YARW. YB-101 received FDA Fast Track; Phase 2a data are expected in 2H 2027.

investegate.co.uk3 min
JUL 28
$VYNELow

Yarrow Bioscience, Inc. (VYNE): Results of Operations and Financial Condition

Yarrow Bioscience, Inc. (VYNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-3.5 6 tm2620687d3_ex3-5.htm EXHIBIT 3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF YARROW BIOSCIENCE, INC. (a Delaware corporation) Article I CORPORATE OFFICES Section 1.1 Registered Office . The registered office of Yarrow Bioscience, Inc., a Delaware corporation (the “ Corpo

SEC EDGAR 8-K6 min
JUL 24
$VYNEMed

VYNE Finalizes Merger With Yarrow, Pays Dividend; To Trade On 1-for-50 Split Basis; Stock Plunges

VYNE Therapeutics said it distributed a special cash dividend to holders of record July 22, 2026, paid July 23, subject to Nasdaq due bill procedures, ahead of a planned 1-for-50 reverse split effective July 24 and split-adjusted trading July 27. VYNE expects merger closing with Yarrow Bioscience early in the week of July 27, with the combined company trading as YARW. VYNE closed at $0.9234.

rttnews.com2 min
JUL 21
$VYNEMed

VYNE Therapeutics Sets 1-for-50 Reverse Stock Split Ahead Of Yarrow Merger

VYNE Therapeutics (VYNE) said its board approved a 1-for-50 reverse stock split tied to its planned merger with Yarrow Bioscience. The split should cut shares from about 33.4M to about 0.7M. The merger is expected to close July 24, 2026, with the combined firm trading July 27 as Yarrow Bioscience (YARW). VYNE also set a special dividend of about $0.40242 per share.

rttnews.com3 min